NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIG
Post# of 124
(Total Views: 110)
Posted On: 03/15/2024 6:02:39 PM
NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space
Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer, ChemoPrep(TM) to enhance the targeted delivery of chemotherapy, ChemoPure(TM) to reduce the toxicity of chemotherapy, and Sigyn Therapy(TM) to address pathogen-associated conditions that are beyond the reach of drugs. “Though highly valued, [immunotherapeutic antibodies to treat cancer] are limited by poor delivery to cancer cell targets and as a result, most patients do not respond to therapy. Inhibiting the delivery of therapeutic antibodies are circulating decoys that display the binding site target of the antibody and can be highly prevalent in the bloodstream. As a result, a significant portion of an antibody dose can bind to circulating decoys instead of cancer cell targets. ‘Amazingly, with more than 1,000 therapeutic antibodies being evaluated by human studies, there was no strategy to reduce the circulating presence of decoys that block the delivery of these drugs,’” reads a recent article that contains excerpts from Sigyn Therapeutics chairman and CEO James A. Joyce’s letter to shareholders.
“To fill this gap, Sigyn Therapy designed the ImmunePrep platform, whose implementation is based on a reverse decoy mechanism. This mechanism will leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that extract antibody decoys from the bloodstream before the normal delivery of the same therapeutic antibodies.”
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://nnw.fm/SIGY
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer, ChemoPrep(TM) to enhance the targeted delivery of chemotherapy, ChemoPure(TM) to reduce the toxicity of chemotherapy, and Sigyn Therapy(TM) to address pathogen-associated conditions that are beyond the reach of drugs. “Though highly valued, [immunotherapeutic antibodies to treat cancer] are limited by poor delivery to cancer cell targets and as a result, most patients do not respond to therapy. Inhibiting the delivery of therapeutic antibodies are circulating decoys that display the binding site target of the antibody and can be highly prevalent in the bloodstream. As a result, a significant portion of an antibody dose can bind to circulating decoys instead of cancer cell targets. ‘Amazingly, with more than 1,000 therapeutic antibodies being evaluated by human studies, there was no strategy to reduce the circulating presence of decoys that block the delivery of these drugs,’” reads a recent article that contains excerpts from Sigyn Therapeutics chairman and CEO James A. Joyce’s letter to shareholders.
“To fill this gap, Sigyn Therapy designed the ImmunePrep platform, whose implementation is based on a reverse decoy mechanism. This mechanism will leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that extract antibody decoys from the bloodstream before the normal delivery of the same therapeutic antibodies.”
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://nnw.fm/SIGY
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Sigyn Therapeutics Inc. (SIGY) Stock Research Links
Scroll down for more posts ▼